Tacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments

Affiliation auteurs!!!! Error affiliation !!!!
TitreTacrines as Therapeutic Agents for Alzheimer's Disease. V. Recent Developments
Type de publicationJournal Article
Year of Publication2021
AuteursBautista-Aguilera OM, Ismaili L, Iriepa I, Diez-Iriepa D, Chabchoub F, Marco-Contelles J, Perez M
JournalCHEMICAL RECORD
Volume21
Pagination162-174
Date PublishedJAN
Type of ArticleArticle
ISSN1527-8999
Mots-clésAlzheimer&apos, Cholinesterase inhibition, Friedl&\#228, Hepatotoxicity, nder reaction, s disease, Tacrine derivatives
Résumé

Herein we have reviewed our recent developments for the identification of new tacrine analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor approved for AD treatment, did not stop the progression of AD, producing only some cognitive improvements, but exhibited secondary effects mainly due to its hepatotoxicity. Thus, the drug was withdrawn from the clinics administration. Since then, many publications have described non-hepatotoxic tacrines, and in addition, important efforts have been made to design multitarget tacrines by combining their cholinesterase inhibition profile with the modulation of other biological targets involved in AD.

DOI10.1002/tcr.202000107